Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 15/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084618 | 0.95 | REN (0.48) | PDE4BRENNPC1APOBEC3ARAB9A | |
| SCHEMBL3074079 | 0.94 | MAPT (0.42) | PDE4BRENMAPT | |
| SCHEMBL3420312 | 0.94 | NPC1 (0.45) | PDE4BRENNPC1APOBEC3ARAB9A | |
| SCHEMBL3082461 | 0.93 | PDE4B (0.43) | PDE4BRENNPC1APOBEC3ARAB9A | |
| SCHEMBL3085683 | 0.93 | PDE4B (0.43) | PDE4BRENNPC1APOBEC3ARAB9A | |
| SCHEMBL3082900 | 0.91 | PDE4B (0.44) | PDE4BREN | |
| SCHEMBL3079274 | 0.91 | REN (0.45) | RENNPC1APOBEC3ARAB9AAPOBEC3G | |
| SCHEMBL3085685 | 0.91 | PDE4B (0.43) | PDE4BRENMAPT | |
| SCHEMBL3083492 | 0.91 | PDE4B (0.43) | PDE4BREN | |
| SCHEMBL3065188 | 0.91 | PDE4B (0.44) | PDE4BREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | PDE4B 312/4885REN 1/4885NPC1 794/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | PDE4B 312/4885REN 1/4885NPC1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.